Virtual Network's Login.
CONFERENCE UPDATE: novel coronavirus (COVID-19)
22nd John Goldman Conference Chronic Myeloid Leukemia: Biology and Therapy
October 01-04, 2020
Chairs: Jorge Cortes, Tim P. Hughes, Daniela S. Krause
Co-organizers: Ravi Bhatia, Tim Brümmendorf, Mhairi Copland, Michael Deininger, Olivier Hantschel, François-Xavier Mahon, Danilo Perrotti, Jerry Radich, Delphine Réa
Advisory Committee: Jane Apperley, Susan Branford, Carlo Gambacorti-Passerini, François Guilhot, Rüdiger Hehlmann, Pierre Laneuville, Giuseppe Saglio, Charles Schiffer, Simona Soverini, Peter Valent, Rick Van Etten
In view of continuing COVID-19 related challenges and uncertainties, ESH has decided to hold this year’s 22nd John Goldman International Conference on Chronic Myeloid Leukemia: Biology and Therapy as a virtual event.
Please note that it will begin one day earlier than initially planned, extending from October 1-4, 2020.
ABOUT THE PROGRAMME:
Speakers at this meeting will present the newest and often unpublished data relating to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells, approaches to cure and treatment free remission.
The programme will include:
MAIN TOPICS:
– Stem Cells and the microenvironment
– Molecular biology and new targets
– Proteomics and Secretomics
– Artificial Intelligence and Machine Learning
– Mechanisms of resistance and disease progression
– Biomarkers
– Immunology and Inflammation
– Therapeutic interventions
– Immunotherapy
– Treatment free remission
– Safety and patient reported outcomes
– Clinical trial design
– The new ELN recommendations
– New drugs in development
ABOUT THE E-CONFERENCE:
Participants will be joining us from all over the world and from different time zones. To make sure that everyone has access to the full scientific programme at a convenient hour, registration will allow participants to join both the LIVE PROGRAMME
and the PROGRAMME ON DEMAND.
– The “Live Programme” is to be found on the programme page. It will be streamed live CEST time, as indicated. It will include lectures, roundtable discussions, Meet the Expert sessions, interactive panel discussions and Q&A periods, and E-Mentored Poster Walks. It will also include some pre-recorded lectures that will be streamed live, followed by their corresponding fully live Q&A period.
– The “Programme on Demand” available as of September 21, 2020, will initially include the pre-recorded components of the scientific programme. It will be progressively enriched by the meeting’s live, interactive components which will be recorded real time during the meeting.
The Virtual platform will remain open from September 21 until October 14, 2020 so that participants can view and review the programme’s full scientific content at times convenient to them.
We have selected a platform with the technical capacity and environment which we feel responds to ESH objectives in terms of learning, scientific interaction and conviviality.
We hope that you will be interested in joining us for this ESH E-Conference on Chronic Myeloid Leukemia,
In the meantime Stay Safe!
The ESH Team
Chairs: Jorge Cortes, Tim P. Hughes, Daniela S. Krause
Co-organizers: Ravi Bhatia, Tim Brümmendorf, Mhairi Copland, Michael Deininger, Olivier Hantschel, François-Xavier Mahon, Danilo Perrotti, Jerry Radich, Delphine Réa
Advisory Committee: Jane Apperley, Susan Branford, Carlo Gambacorti-Passerini, François Guilhot, Rüdiger Hehlmann, Pierre Laneuville, Giuseppe Saglio, Charles Schiffer, Simona Soverini, Peter Valent, Rick Van Etten
Upon completion of this CME activity, participants should be able to:
1. Understand current and new concepts of the signal transduction pathways involved in chronic myeloid leukemia (CML) and the mechanisms of action of tyrosine kinase inhibitors and other new agents.
2. Have insight into the possible mechanisms of genomic instability that predisposes to formation of the BCR-ABL fusion gene and predispose also to disease progression and the consequences of such instability.
3. Define a leukemia stem cell and its relationship to disease kinetics in so far as current knowledge permits.
4. Evaluate the merits of various management decisions, e.g. how to start treatment for patients in the different phases of CML, how to assess success or failure of initial treatment, what approaches to consider for patients who have failed to respond well to initial treatment, including assessing the precise role of second and third generation TKIs and other non-molecular therapeutic approaches.
5. Review the current recommendations and discuss current concepts and challenges of monitoring individual patients with hematologic, cytogenetic and molecular (RQ-PCR) methods.
6. Assess the role of allogeneic stem cell transplantation in the management of CML.
7. Critically evaluate the possible role of the different immunotherapeutic approaches in the treatment of CML.
8. Discuss current data and ongoing research regarding treatment-free survival as an endpoint in CML management.
9. Discuss patient reported outcomes and their role in the management of patients with CML.
Abstracts guidelines:
– Your abstract has to be structured (eg Objectives, Methods, Results, Conclusions)
– Maximum number of words: 400
– Your abstract will be submitted to the peer review procedure.
The following file types may be uploaded: HTML document (*.htm), HTML document (*.html), JPEG image (*.jpg), GIF image (*.gif), or PNG image (*.png).
N/A
Conference moving online, click here to access and visit the E-Conference platform.
With the support of*
Emerald Conference Partners
**********
Ruby Conference Partner
**********
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.
ESH SCHOLARSHIP FUND
LEUKAEMIA UK INTERNATIONAL SCHOLARSHIPS are available!
INFORMATION AND APPLICATION FORM
The ESH Scholarship Fund is a multi-sponsored project designed to support access to new biological and clinical data in the context of lifelong learning in Haematology.
ESH independently ensures all scientific peer review and selection procedures.
ESH is also independently responsible for all administrative aspects of the Fund.
Applications are closed
This Call for Applications is made thanks to a funding support from
to the ESH Scholarship Fund
The registration fee for the “22nd John Goldman E-Conference Chronic Myeloid Leukemia: Biology and Therapy” is:
– Fully trained: 80€
– In-training: 50€
– Allied Health Professionals: 50€
– Corporate: 150€
A proof will be requested to confirm your status.
This fee includes:
– Access to the on demand programme from September 21 till October 14, 2020
– Access to the live programme
– Access to the Conference E-Book from October 1 till October 14, 2020
– Access to the E-Poster Area from September 21 till October 14, 2020
– Access to the E-Poster Walk session
Your access to the conference will be definitively confirmed upon receipt of your fee.
IMPORTANT NOTE:
MEET THE EXPERT SESSIONS registration will open closer to the E-CONFERENCE (extra fee of 20€ per session).
How to proceed :
Please make sure that your Internet browser (Firefox, Safari, Google Chrome…) is up-to-date. Using an old version may prevent you from visualising the full website content.
Cancellation policy of registration fee:
In case of cancellation, up until 3 months prior to the beginning of the meeting, your registration fee will be reimbursed in full (less bank charges). If the cancellation is notified after this delay your registration to the meeting will not be reimbursed.
